GSK to face FDA meeting over Avandia safety record
Wednesday 24 February 2010
The Food and Drug Administration (FDA) will hold a public meeting on the possible heart risks of GlaxoSmith-Kline's (GSK) diabetes treatment Avandia in July, the US regulator said yesterday, but it urged doctors to continue prescribing the drug until any new advice was issued.
The move came after Rosa DeLauro, a Democratic Representative in Congress, posted a notice on her website on Saturday saying the FDA should "remove Avandia from the market until a truly independent, science-based advisory panel can evaluate the safety and effectiveness of the drug".
Ms DeLauro, the chairman of the agriculture subcommittee of the Committee on Appropriations, which funds the FDA, was reacting to the release of documents in Congress, including a memo from two FDA safety officials who recommended Avandia should be withdrawn from the US. They said the drug posed a greater risk of heart attacks than alternative treatments.
GSK said the FDA had conducted seven trials into the cardiovascular safety of Avandia since 2007, when concerns were first raised. "None of these randomised clinical trials, which remain the gold standard for evaluating scientific and medical questions, shows a statistically significant association between Avandia and heart attack or other ischemic cardiovascular events."
Avandia sales were worth $3bn (£1.9bn) in 2006, before an article written by the Cleveland cardiologist Steven Nissen in the respected New England Journal of Medicine cast doubts over Avandia's safety. In 2009, GSK made $1.2bn (£780m) from Avandia sales.
Dr Nissen recorded a meeting he held with GSK executives days before his research was published. He told The New York Times that he feared he would come under pressure to change his work. The Congressional report issued on Saturday said that scientists critical of Avandia's safety had been threatened by the company.
GSK rejected the report, saying it "cherry-picks information from documents, which mischaracterizes [sic] GlaxoSmithKline's comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients".
- 1 Tourist films plane's descent just metres above packed Caribbean beach
- 2 Kate Moss: Previously unpublished nude photo revealed by Mert and Marcus
- 3 Indian woman creates 'Marriage CV' after parents put her on dating site: 'Definitely not marriage material. Won’t grow long hair, ever'
- 4 World Book Day: Boy 'excluded' from school after dressing up as Fifty Shades' Christian Grey
- 5 Bad Jews poster 'censored' on London Tube
Tourist films plane's descent just metres above packed Caribbean beach
Indian woman creates 'Marriage CV' after parents put her on dating site: 'Definitely not marriage material. Won’t grow long hair, ever'
Becky Watts: Four appear in court charged with hiding body parts after teenager's death
Isis 'bulldozes' Nimrud: UNESCO condemns destruction of ancient Assyrian site as a 'war crime'
Professor Brian Cox brands astrology-believing Tory MP David Tredinnick an 'outlier on the spectrum of reason'
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Durham Free School: 'Creationism taught at' free school facing closure
End of the licence fee: BBC to back radical overhaul of how it is funded
Elif Shafak: Turkish author warns against rise of British nationalism
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
iJobs Money & Business
£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£12 - £15 Hourly Rate: Jemma Gent: In this role you will report to the Head of...
£8 per hour: Recruitment Genius: This Pension Specialist was established early...